| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.62 | 0.02 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.27 | 0.3 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.2 | 2e-08 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.19 | 0.0003 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.18 | 0.003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.18 | 1e-06 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.17 | 0.0007 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.009 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0004 |